In a nutshell This article reviewed new developments in treatments for patients with Hodgkin lymphoma (HL). Some background For most patients with HL, conventional treatments such as chemotherapy are effective. However, about 50 – 60% of patients have cancer come back (relapse) or become resistant to treatment (refractory). High-dose...
Read MoreIn a nutshell This study aimed to investigate the frequency of advanced colorectal neoplasia (ACN; abnormal growth of tissue in the bowel) in Hodgkin lymphoma (HL) survivors. This study concluded that HL survivors treated with abdominal radiotherapy and/or alkylating chemotherapy have a high frequency of ACN. Some background...
Read More
In a nutshell This study compared the effectiveness of the International Prognostic Scoring System (IPSS) measuring 7 factors (IPSS7) versus the IPSS measuring 3 factors (IPSS3) in predicting outcomes for patients with Hodgkin's lymphoma (HL). This study concluded that there was no significant difference between these scoring systems. Some...
Read MoreIn a nutshell This study will investigate the effects of pembrolizumab (Keytruda) and targeted radiation therapy for relapsed or unresponsive Hodgkin lymphoma (HL). This study will measure the rate of complete response (disappearance of all cancer). The details Many patients are cured with treatments for HL. Some patients lose response to...
Read More
In a nutshell This study aimed to investigate treatments and outcomes for patients with relapsed or unresponsive nodular lymphocyte-predominant Hodgkin lymphoma. This study concluded that these patients have a good overall prognosis and treatments should be chosen individually. Some background Radiotherapy (RT), chemotherapy (CT) and rituximab...
Read More
In a nutshell This study evaluated the long-term outcomes of patients with recurrent or non-responsive classical Hodgkin’s lymphoma (cHL) after undergoing radiation, chemotherapy, and autologous stem cell transplantation (autoSCT). This study concluded that total lymphoid irradiation (TLI) therapy before a bone marrow transplant can improve...
Read More
In a nutshell This study aimed to compare outcomes for patients with Hodgkin’s lymphoma who received brentuximab vedotin (Adcetris) compared to chemotherapy before a stem cell transplant. This study concluded that patients who received brentuximab vedotin had a better survival. Some background Allogeneic hematopoietic stem cell...
Read MoreIn a nutshell This study evaluated the safety and effectiveness of two chemotherapy regimens before autologous stem cell transplantation (ASCT) for patients with Hodgkin lymphoma (HL). This study concluded that BEAM conditioning before ASCT significantly improved the outcomes of these patients. Some background About 20 – 30% of patients...
Read More
In a nutshell This trial is examining the safety and effectiveness of pembrolizumab (Keytruda) in the treatment of children and young adults with classical Hodgkin lymphoma (HL). The main outcome to be measured will be a response to treatment. This trial is recruiting in the Republic of Korea and the United States. The details...
Read More
In a nutshell This study evaluated the safety and effectiveness of PD-1 inhibitors for patients with classical Hodgkin lymphoma (cHL) outside of clinical trials. This study concluded that PD-1 inhibitors are safe and effective for these patients. Some background Standard first-line chemotherapy is highly effective in treating 70 – 80% of...
Read More
In a nutshell This study examined whether listening to music during chemotherapy reduces anxiety in patients with newly diagnosed lymphoma. This study concluded that live music reduced anxiety in these patients. Some background During and after chemotherapy treatment, patients with lymphoma may experience severe anxiety. Fearful thoughts about the...
Read More
In a nutshell This study aimed to investigate the impact of donor type and melphalan (Alkeran) dose on transplant outcomes for patients with lymphoma. This study concluded that different donor types and melphalan doses have similar outcomes for these patients. Some background Allogenic hematopoietic stem cell transplant (allo-HSCT) is a...
Read More
